Zum Inhalt springen

German health authority rejects added value of amyloid drugs in Alzheimer’s treatment

The German health authority has rejected added value claims for several Alzheimer's medications

New research from Magdeburg suggests that memory loss in Alzheimer’s disease may not be permanent, challenging the long-held assumption that cognitive decline stems solely from irreversible brain cell death. A review of 17 studies involving over 20,000 participants found that widely used anti-amyloid drugs like Lecanemab reduce brain plaque but deliver minimal clinical benefit after … Weiterlesen …